Cencora Reports Strong Q1, Raises Guidance, Completes $4.6B OneOncology Acquisition

summarizeSummary

Cencora reported strong Q1 fiscal 2026 earnings, raised its adjusted operating income guidance, and completed a $4.6 billion acquisition of OneOncology, signaling robust strategic growth.

check_boxKey Events

• Strong Q1 Fiscal 2026 Results

  Reported revenue of $85.9 billion (up 5.5% year-over-year) and adjusted diluted EPS of $4.08 (up 9.4% year-over-year) for the quarter ended December 31, 2025.

• Raised Operating Income Guidance

  Increased fiscal 2026 adjusted operating income growth guidance from 8-10% to 11.5-13.5%, primarily due to the OneOncology acquisition and U.S. Healthcare Solutions performance.

• Completes $4.6 Billion OneOncology Acquisition

  Acquired the majority of outstanding equity interests in OneOncology for approximately $4.6 billion in cash, funded through new debt financing. This follows the securing of $4.5 billion in term loan facilities on January 16, 2026.

• Asset Impairment Disclosure

  Disclosed a $249.5 million impairment of assets related to its U.S. Consulting Services business, which is classified as held for sale.

auto_awesomeAnalysis

Cencora, Inc. delivered robust first-quarter fiscal 2026 results, exceeding expectations with a 5.5% increase in revenue and a 9.4% rise in adjusted diluted EPS. The company significantly raised its adjusted operating income guidance for fiscal 2026, primarily driven by the recently completed $4.6 billion acquisition of OneOncology. This strategic acquisition, funded by new debt facilities secured in January, expands Cencora's specialty MSO footprint and deepens its presence in cancer care. While the company also reported a $249.5 million asset impairment related to a divested consulting business, the overall financial performance and strategic expansion signal strong operational momentum and a positive outlook, especially as the stock trades near its 52-week high.